Results 81 to 90 of about 9,786 (244)
Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders [PDF]
Non-transferrin-bound iron and its labile (redox active) plasma iron component are thought to be potentially toxic forms of iron originally identified in the serum of patients with iron overload.
Biemond, BJ+17 more
core +8 more sources
Oxidative Stress: Signaling Pathways, Biological Functions, and Disease
Oxidative stress causes cellular damage across multiple systems, contributing to neurodegeneration (Alzheimer's, Parkinson's, Huntington's), cancer progression and resistance, cardiovascular diseases (atherosclerosis, heart failure), liver and kidney injury, metabolic disorders (diabetes, obesity), autoimmune diseases, musculoskeletal decline, retinal ...
Sixuan Liu+4 more
wiley +1 more source
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
Thalassemia incorporates a broad clinical spectrum characterized by decreased or absent production of normal hemoglobin leading to decreased red blood cell survival and ineffective erythropoiesis. Chronic iron overload remains an inevitable complication resulting from regular blood transfusions (transfusion-dependent) and/or increased iron absorption ...
Rayan Bou-Fakhredin+2 more
openaire +5 more sources
Abstract Background The radiation‐induced abscopal effect (RIAE) is a desirable phenomenon involving radiation‐induced activation of the immune system and regression of metastatic disease after local radiotherapy. However, the majority of patients undergoing radiotherapy do not experience abscopal responses.
Deng‐Yuan Chang+2 more
wiley +1 more source
Investigating the Effect of Iron Chelation Therapy With Deferasirox on Liver Aminotransferases Levels in Transfusion-dependent β-thalassemia Patients [PDF]
Background Various body tissues of β-thalassemia patients are exposed to the destructive effects of iron overload due to chronic blood transfusions. Therefore, the decision to start regular blood transfusion therapy for these patients often leads to the ...
Shayan Pourkazem+7 more
doaj
BACKGROUND:Iron overload, resulting from blood transfusions in patients with chronic anemias, has historically been controlled with regular deferoxamine, but its parenteral requirement encouraged studies of orally-active agents, including deferasirox and
Nancy F Olivieri+2 more
doaj +1 more source
Objective: To evaluate efficacy, safety and utilization pattern of deferasirox in paediatric patients of transfusion dependant β Thalassemia Major at a tertiary care teaching hospital in Gujarat.
Dhaval R Thakor+4 more
doaj +1 more source
Iron chelating agents for iron overload diseases [PDF]
Although iron is an essential element for life, an excessive amount may become extremely toxic both for its ability to generate reactive oxygen species, and for the lack in humans of regulatory mechanisms for iron excretion.
Crisponi, Guido+2 more
core +2 more sources
Ferroptosis, a controlled cell death, is driven by iron and characterized by reactive oxygen species and lipid peroxidation. The impact of lipid peroxides, GSH/GPX4, and iron metabolism–targeting small molecule inhibitors is discussed. Nucleic acids, proteins, and phytochemicals are implicated as inhibitors of ferroptosis.
Anwar Ali+10 more
wiley +1 more source
In vitro Studying of Deferasirox Side effects on the Structure and the Function of Bovine Liver Catalase [PDF]
Background & Objective: Oral chelators such as deferasirox are used to treat iron overload caused by blood transfusion. Considering the significant role of liver in detoxification and drug metabolism as well as the importance of catalase as a key enzyme ...
Maryam Moradi+4 more
doaj +1 more source